Influenza Surveillance
Vaccine Recommendations
Samples Received
Surveillance Data


Contact
WHO Collaborating Centre for Reference and Research on Influenza (VIDRL)
Peter Doherty Institute for Infection and Immunity
792 Elizabeth Street
Melbourne VIC 3000 Australia

T +61 3 9342 9300
F +61 3 9342 9329
whoflu@influenzacentre.org


Current Vaccine Recomendations

8 March 2017

2017-18 WHO Northern Hemisphere recommendations

It is recommended that trivalent vaccines for use in the 2017-2018 influenza season (northern hemisphere winter) contain the following:

  •   an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  •   an A/Hong Kong/4801/2014 (H3N2)-like virus;
  •   a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus.

Full WHO Recommendation


4 October 2016

2017 WHO Southern Hemisphere recommendations

It is recommended that trivalent vaccines for use in the 2017 influenza season (southern hemisphere winter) contain the following:

  •   an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  •   an A/Hong Kong/4801/2014 (H3N2)-like virus;
  •   a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus.

Full WHO Recommendation


2 November 2016

Australian Influenza Vaccine Committee (AIVC) decision on the Influenza vaccine virus composition for Australia 2017

The AIVC met on 13 October 2016 and decided that the Australian influenza vaccine for 2017 should contain the following:

  • A (H1N1): an A/Michigan/45/2015 (H1N1)pdm09-like virus
  • A (H3N2): an A/Hong Kong/4801/2014 (H3N2)-like virus
  • B: a B/Brisbane/60/2008-like virus

Quadrivalent vaccines should contain viruses listed above, plus the additional B virus:

  • B/Phuket/3073/2013-like virus.

See the TGA website for further information.